Prospective Assessment of Acute Skin Toxicities in Breast Cancer Patients Undergoing Retreatment with 40 Gy in 15 Fractions Radiation Therapy

Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Dec 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a specific type of radiation therapy on breast cancer patients who have previously received radiation treatment. The researchers want to understand how this new treatment, which involves delivering a lower dose of radiation over a shorter period (40 Gy in 15 fractions), affects the skin and whether it leads to any skin problems, known as skin toxicities. This is important because many patients experience skin issues after radiation, which can affect their quality of life.

To be eligible for the trial, participants must be at least 18 years old, have a confirmed diagnosis of breast cancer, and have already received radiation for breast cancer in the past. They should also be scheduled to receive this new radiation treatment. Participants can expect to undergo assessments related to their skin condition during the trial, which will help researchers learn more about the safety and effectiveness of this treatment approach. This study is currently recruiting participants, and those interested should discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old
• • Informed consent
• • Histological confirmation of breast malignancy (invasive or in situ carcinoma) or phyllodes
• • Previous history of ipsilateral breast cancer treated with RT
• • Patients are planned to receive hypofractionated (40Gy/15) RT to the whole or partial breast or chest wall
• • Patients treated with or without the addition of a planned boost or bolus
• • Patients receiving local or locoregional radiation treatment
• • Can communicate in English or be aided by a translator
• Exclusion Criteria:
• • Patients scheduled to receive conventionally fractionated (50Gy/25 or 45Gy/25) or extreme hypofractionation (26Gy/5)
• • Patients planned to receive brachytherapy
• • Patients with active rash, pre-existing dermatitis, or other conditions within the treatment area that may make skin assessment for the study difficult per treating physician discretion
• • Concomitant cytotoxic chemotherapy
• • Scleroderma